Physician profile
Claudia Mily Espinosa
NPI 1093840522
$75,277.82
in general payments reported to CMS, 2019-2025
11 companies · $19K in 2025
The $19K reported for 2025 was more than what 90% of Pediatric Infectious Diseases providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,622 · 2020: $9,682 · 2021: $2,236 · 2022: $18K · 2023: $15K · 2024: $4,136 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $14K · Travel and Lodging: $5,728 · Food and Beverage: $1,515 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,385.00 |
| Consulting Fee | $14,425.00 |
| Travel and Lodging | $5,728.48 |
| Food and Beverage | $1,514.52 |
| Education | $324.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39,259.59 | 2020-2025 | |
| Astellas Pharma US INC | $22,188.14 | 2024-2025 | Cresemba |
| Gilead Sciences, INC. | $10,822.03 | 2019-2023 | Vemlidy |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2021 | |
| Merck Sharp & Dohme LLC | $677.27 | 2025 | |
| Sobi, INC | $216.13 | 2021 | |
| Abbvie INC. | $94.66 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.